cholecalciferol and Fibrous-Dysplasia--Polyostotic

cholecalciferol has been researched along with Fibrous-Dysplasia--Polyostotic* in 4 studies

Reviews

2 review(s) available for cholecalciferol and Fibrous-Dysplasia--Polyostotic

Article	Year
[Pseudohypoparathyroidism]. Ryoikibetsu shokogun shirizu, 2000, Issue:29 Pt 4 Topics: Cholecalciferol; Diagnosis, Differential; Fibrous Dysplasia, Polyostotic; Humans; Mental Disorders; Prognosis; Pseudohypoparathyroidism	2000
[Physiopathology and therapy of pseudohypoparathyroidism and pseudopseudohypoparathyroidism]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 1999, Jul-10, Volume: 88, Issue:7 Topics: Cholecalciferol; Diagnosis, Differential; Fibrous Dysplasia, Polyostotic; Humans; Parathyroid Hormone; Pseudohypoparathyroidism; Pseudopseudohypoparathyroidism	1999

Other Studies

2 other study(ies) available for cholecalciferol and Fibrous-Dysplasia--Polyostotic

Article	Year
Alendronate therapy in polyostotic fibrous dysplasia presenting with pathologic fracture. American journal of orthopedics (Belle Mead, N.J.), 2011, Volume: 40, Issue:3 Polyostotic fibrous dysplasia (PFD) is characterized by developmental failure in the remodeling of primitive bone to mature lamellar bone. PFD presents with bone pain, increased bone fragility, deformities, and fractures. Bisphosphonates are the only agents available for medical management.1,2 Intravenous (IV) pamidronate is the established treatment for symptomatic bone involvement in PFD.3,4 Oral alendronate holds promise because of its comparable outcomes, lower cost, and ease of administration.5 The patient described in this case report provided written informed consent for its print and electronic publication after reviewing the complete manuscript and skeletal radiographic images. Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium Carbonate; Cholecalciferol; Diagnosis, Differential; Drug Therapy, Combination; Female; Fibrous Dysplasia, Polyostotic; Fractures, Bone; Humans; Radiography; Treatment Outcome	2011
[Proceedings: Polyostatic fibrous dysplasia with vitamin D-resistant rachitis]. Monatsschrift fur Kinderheilkunde, 1975, Volume: 123, Issue:5 Topics: Adolescent; Child; Child, Preschool; Cholecalciferol; Female; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Humans; Hypophosphatemia, Familial; Phosphates	1975

Article

Year

Alendronate therapy in polyostotic fibrous dysplasia presenting with pathologic fracture.

American journal of orthopedics (Belle Mead, N.J.), 2011, Volume: 40, Issue:3

Polyostotic fibrous dysplasia (PFD) is characterized by developmental failure in the remodeling of primitive bone to mature lamellar bone. PFD presents with bone pain, increased bone fragility, deformities, and fractures. Bisphosphonates are the only agents available for medical management.1,2 Intravenous (IV) pamidronate is the established treatment for symptomatic bone involvement in PFD.3,4 Oral alendronate holds promise because of its comparable outcomes, lower cost, and ease of administration.5 The patient described in this case report provided written informed consent for its print and electronic publication after reviewing the complete manuscript and skeletal radiographic images.

Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium Carbonate; Cholecalciferol; Diagnosis, Differential; Drug Therapy, Combination; Female; Fibrous Dysplasia, Polyostotic; Fractures, Bone; Humans; Radiography; Treatment Outcome

2011

[Proceedings: Polyostatic fibrous dysplasia with vitamin D-resistant rachitis].

Monatsschrift fur Kinderheilkunde, 1975, Volume: 123, Issue:5

Topics: Adolescent; Child; Child, Preschool; Cholecalciferol; Female; Fibrous Dysplasia of Bone; Fibrous Dysplasia, Polyostotic; Humans; Hypophosphatemia, Familial; Phosphates

1975